
Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, discusses the impact of the APHINITY trial on the treatment of patients with HER2-positive breast cancer.

Published: November 14th 2018 | Updated:

Published: November 29th 2018 | Updated: